Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro

Thomas H. Kramer, Geza Toth, Ronald C. Haaseth, Terry O Matsunaga, Peg Davis, Victor J Hruby, Thomas F. Burks

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Several peptides of diverse structure, reported to possess high affinity and selectivity for the δ opioid receptor, were studied using the mouse isolated vas deferens preparation to determine the effect of peptidase inhibition on their apparent potency. The peptides evaluated included [Leu5]enkephalin, the cyclic enkephalin analogs [D-Pen2, D-Pen5] enkephalin (DPDPE) and [D-Pen2, p-F-Phe4, D-Pen5]enkephalin (F-DPDPE), the linear enkephalin analogs [D-Ala2, D-Leu5]enkephalin (DADLE) and [D-Ser2(O-tBu), Leu5, Thr6]enkephalin (DSTBULET), and the naturally occurring amphibian peptides Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 (dermenkephalin), Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II). Concentration-response curves were determined for each peptide in the absence and presence of a combination of the peptidase-inhibiting agents bacitracin, bestatin, and captopril. A wide range of potencies was observed, both in the control state and in the presence of peptidase inhibition. The synthetic enkephalin analogs demonstrated small increases in potency with peptidase inhibition (no increase in the case of DPDPE), whereas the naturally occurring peptides were markedly increased in potency, up to as much as 123-fold for dermenkephalin. In the presence of peptidase inhibition, deltorphin II was the most potent peptide tested (IC50 = 1.13 X 10-10 molar), and as such is the most potent delta opioid agonist reported to date. Stability to metabolism must be considered in the design and evaluation of in vitro experiments using peptides of this type.

Original languageEnglish (US)
Pages (from-to)881-886
Number of pages6
JournalLife Sciences
Volume48
Issue number9
DOIs
StatePublished - 1991

Fingerprint

Opioid Peptides
Protease Inhibitors
Enkephalins
D-Penicillamine (2,5)-Enkephalin
Peptides
Peptide Hydrolases
Bacitracin
Vas Deferens
Captopril
Opioid Receptors
Amphibians
In Vitro Techniques
Metabolism
Opioid Analgesics
Inhibitory Concentration 50
Ala(2)-enkephalinamide-met
Ala(2)-deltorphin II
deltorphin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro. / Kramer, Thomas H.; Toth, Geza; Haaseth, Ronald C.; Matsunaga, Terry O; Davis, Peg; Hruby, Victor J; Burks, Thomas F.

In: Life Sciences, Vol. 48, No. 9, 1991, p. 881-886.

Research output: Contribution to journalArticle

Kramer, Thomas H. ; Toth, Geza ; Haaseth, Ronald C. ; Matsunaga, Terry O ; Davis, Peg ; Hruby, Victor J ; Burks, Thomas F. / Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro. In: Life Sciences. 1991 ; Vol. 48, No. 9. pp. 881-886.
@article{4d51f49010644a57aa378ec999eca341,
title = "Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro",
abstract = "Several peptides of diverse structure, reported to possess high affinity and selectivity for the δ opioid receptor, were studied using the mouse isolated vas deferens preparation to determine the effect of peptidase inhibition on their apparent potency. The peptides evaluated included [Leu5]enkephalin, the cyclic enkephalin analogs [D-Pen2, D-Pen5] enkephalin (DPDPE) and [D-Pen2, p-F-Phe4, D-Pen5]enkephalin (F-DPDPE), the linear enkephalin analogs [D-Ala2, D-Leu5]enkephalin (DADLE) and [D-Ser2(O-tBu), Leu5, Thr6]enkephalin (DSTBULET), and the naturally occurring amphibian peptides Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 (dermenkephalin), Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II). Concentration-response curves were determined for each peptide in the absence and presence of a combination of the peptidase-inhibiting agents bacitracin, bestatin, and captopril. A wide range of potencies was observed, both in the control state and in the presence of peptidase inhibition. The synthetic enkephalin analogs demonstrated small increases in potency with peptidase inhibition (no increase in the case of DPDPE), whereas the naturally occurring peptides were markedly increased in potency, up to as much as 123-fold for dermenkephalin. In the presence of peptidase inhibition, deltorphin II was the most potent peptide tested (IC50 = 1.13 X 10-10 molar), and as such is the most potent delta opioid agonist reported to date. Stability to metabolism must be considered in the design and evaluation of in vitro experiments using peptides of this type.",
author = "Kramer, {Thomas H.} and Geza Toth and Haaseth, {Ronald C.} and Matsunaga, {Terry O} and Peg Davis and Hruby, {Victor J} and Burks, {Thomas F.}",
year = "1991",
doi = "10.1016/0024-3205(91)90034-9",
language = "English (US)",
volume = "48",
pages = "881--886",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro

AU - Kramer, Thomas H.

AU - Toth, Geza

AU - Haaseth, Ronald C.

AU - Matsunaga, Terry O

AU - Davis, Peg

AU - Hruby, Victor J

AU - Burks, Thomas F.

PY - 1991

Y1 - 1991

N2 - Several peptides of diverse structure, reported to possess high affinity and selectivity for the δ opioid receptor, were studied using the mouse isolated vas deferens preparation to determine the effect of peptidase inhibition on their apparent potency. The peptides evaluated included [Leu5]enkephalin, the cyclic enkephalin analogs [D-Pen2, D-Pen5] enkephalin (DPDPE) and [D-Pen2, p-F-Phe4, D-Pen5]enkephalin (F-DPDPE), the linear enkephalin analogs [D-Ala2, D-Leu5]enkephalin (DADLE) and [D-Ser2(O-tBu), Leu5, Thr6]enkephalin (DSTBULET), and the naturally occurring amphibian peptides Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 (dermenkephalin), Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II). Concentration-response curves were determined for each peptide in the absence and presence of a combination of the peptidase-inhibiting agents bacitracin, bestatin, and captopril. A wide range of potencies was observed, both in the control state and in the presence of peptidase inhibition. The synthetic enkephalin analogs demonstrated small increases in potency with peptidase inhibition (no increase in the case of DPDPE), whereas the naturally occurring peptides were markedly increased in potency, up to as much as 123-fold for dermenkephalin. In the presence of peptidase inhibition, deltorphin II was the most potent peptide tested (IC50 = 1.13 X 10-10 molar), and as such is the most potent delta opioid agonist reported to date. Stability to metabolism must be considered in the design and evaluation of in vitro experiments using peptides of this type.

AB - Several peptides of diverse structure, reported to possess high affinity and selectivity for the δ opioid receptor, were studied using the mouse isolated vas deferens preparation to determine the effect of peptidase inhibition on their apparent potency. The peptides evaluated included [Leu5]enkephalin, the cyclic enkephalin analogs [D-Pen2, D-Pen5] enkephalin (DPDPE) and [D-Pen2, p-F-Phe4, D-Pen5]enkephalin (F-DPDPE), the linear enkephalin analogs [D-Ala2, D-Leu5]enkephalin (DADLE) and [D-Ser2(O-tBu), Leu5, Thr6]enkephalin (DSTBULET), and the naturally occurring amphibian peptides Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 (dermenkephalin), Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II). Concentration-response curves were determined for each peptide in the absence and presence of a combination of the peptidase-inhibiting agents bacitracin, bestatin, and captopril. A wide range of potencies was observed, both in the control state and in the presence of peptidase inhibition. The synthetic enkephalin analogs demonstrated small increases in potency with peptidase inhibition (no increase in the case of DPDPE), whereas the naturally occurring peptides were markedly increased in potency, up to as much as 123-fold for dermenkephalin. In the presence of peptidase inhibition, deltorphin II was the most potent peptide tested (IC50 = 1.13 X 10-10 molar), and as such is the most potent delta opioid agonist reported to date. Stability to metabolism must be considered in the design and evaluation of in vitro experiments using peptides of this type.

UR - http://www.scopus.com/inward/record.url?scp=0026023804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026023804&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(91)90034-9

DO - 10.1016/0024-3205(91)90034-9

M3 - Article

VL - 48

SP - 881

EP - 886

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 9

ER -